This wealth manager just dumped his entire $3.5 million stake in the iShares Biotech ETF
Sold 24,270 IBB shares; Estimated trade value of $3.50 million based on quarterly average price. The net value of the position decreased by $3.50 million. It represents a 3.27% change in 13F reportable assets under management. Rye Brook Capital now owns no shares and has no remaining value in IBB. The sale comes amid reduced…